Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: study protocol for a randomized controlled trial

Jesús Villar, Javier Belda, José Manuel Añón, Jesús Blanco, Lina Pérez-Méndez, Carlos Ferrando, Domingo Martínez, Juan Alfonso Soler, Alfonso Ambrós, Tomás Muñoz, Rosana Rivas, Ruth Corpas, Francisco J Díaz-Dominguez, Marina Soro, Miguel Angel García-Bello, Rosa Lidia Fernández, Robert M Kacmarek, DEXA-ARDS Network, Jesús Villar, Javier Belda, José Manuel Añón, Jesús Blanco, Lina Pérez-Méndez, Carlos Ferrando, Domingo Martínez, Juan Alfonso Soler, Alfonso Ambrós, Tomás Muñoz, Rosana Rivas, Ruth Corpas, Francisco J Díaz-Dominguez, Marina Soro, Miguel Angel García-Bello, Rosa Lidia Fernández, Robert M Kacmarek, DEXA-ARDS Network

Abstract

Background: Although much has evolved in our understanding of the pathogenesis and factors affecting outcome of patients with acute respiratory distress syndrome (ARDS), still there is no specific pharmacologic treatment for ARDS. Several clinical trials have evaluated the utility of corticoids but none of them has demonstrated a definitive benefit due to small sample sizes, selection bias, patient heterogeneity, and time of initiation of treatment or duration of therapy. We postulated that adjunctive treatment of persistent ARDS with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and a decrease in mortality.

Methods/design: This is a prospective, multicenter, randomized, controlled trial in 314 patients with persistent moderate/severe ARDS. Persistent ARDS is defined as maintaining a PaO2/FiO2 ≤ 200 mmHg on PEEP ≥ 10 cmH2O and FiO2 ≥ 0.5 after 24 hours of routine intensive care. Eligible patients will be randomly allocated to two arms: (i) conventional treatment without dexamethasone, (ii) conventional treatment plus dexamethasone. Patients in the dexamethasone group will be treated with a daily dose of 20 mg iv from day 1 to day 5, and 10 mg iv from day 6 to day 10. Primary outcome is the number of ventilator-free days, defined as days alive and free from mechanical ventilation at day 28 after intubation. Secondary outcome is all-cause mortality at day 60 after enrollment.

Discussion: This study will be the largest randomized controlled clinical trial to assess the role of dexamethasone in patients with persistent ARDS.

Trial registration: Registered on 21 November 2012 as DEXA-ARDS at ClinicalTrials.gov website ( NCT01731795 ).

Keywords: Acute respiratory distress syndrome; Corticoids; Dexamethasone; Lung-protective ventilation; Positive end-expiratory pressure.

Figures

Fig. 1
Fig. 1
Study design diagram
Fig. 2
Fig. 2
Schedule of events
Fig. 3
Fig. 3
Estimation of samples size calculations based on expected ventilator-free days and mortality. Power analysis has been performed according to Schoenfeld et al [32]. Since we need three probabilities (see Table 1, text highlighted in yellow), we have selected three probabilities compatible with our hypothesis (using Mann-Whitney test). We hypothesized that patients in the experimental treatment group have a greater probability of being weaned earlier from the ventilator (0.0641 vs. 0.481) and a lower probability of dying (0.0345 vs. 0.05) for each day of the follow-up period

References

    1. Villar J, Blanco J, Kacmarek RM. Acute respiratory distress syndrome definition: do we need a change? Curr Opin Crit Care. 2011;17:13–7. doi: 10.1097/MCC.0b013e32834271fb.
    1. Villar J, Blanco J, Añón JM, Santos-Bouza A, Blanch L, Ambrós A, Gandía F, Carriedo D, Mosteiro F, Basaldúa S, Fernández RL, Kacmarek RM. The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med. 2011;7:1932–41.
    1. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids – new mechanism for old drugs. N Engl J Med. 2005;353:1711–23. doi: 10.1056/NEJMra050541.
    1. Monton C, Ewig S, Torres A, El-Ebiary M, Filella X, Rañó A, Xaubet A. Role of glucocorticoids on inflammatory response in nonimmunosupressed patients with pneumonia: a pilot study. Eur Respir J. 1999;14:218–20.
    1. Weigelt JA, Norcross JF, Borman KR, Snyder WH., III Early steroid therapy for respiratory failure. Arch Surg. 1985;120:536–40. doi: 10.1001/archsurg.1985.01390290018003.
    1. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988;138:62–8. doi: 10.1164/ajrccm/138.1.62.
    1. Bone RC, Fisher CJ, Jr, Clemmer TP, Slotman GJ, Metz CA. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest. 1987;92:1032–6. doi: 10.1378/chest.92.6.1032.
    1. Bernard GR. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317:1565–70. doi: 10.1056/NEJM198712173172504.
    1. Hooper RG, Kearl RA. Established ARDS with a sustained course of adrenocortical steroids. Chest. 1990;97:138–43. doi: 10.1378/chest.97.1.138.
    1. Meduri GU, Belenchia JM, Estes RJ, Wunderink RG, el Torky M, Leeper KV., Jr Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. Chest. 1991;100:943–52. doi: 10.1378/chest.100.4.943.
    1. Meduri GU, Chinn AJ, Leeper KV, Wunderink RG, Tolley E, Winer-Muram HT, Khare V, Eltorky M. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Patterns of response and predictors of outcome. Chest. 1994;105:1516–27.
    1. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, Tolley EA. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280:159–65.
    1. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, Thompson BT, Ancukiewicz M, National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354:1671–84.
    1. Annane D, Sebille V, Bellissant E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med. 2006;34:22–30. doi: 10.1097/01.CCM.0000194723.78632.62.
    1. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131:954–63. doi: 10.1378/chest.06-2100.
    1. Tang BM, Craig JC, Eslick GD, Seppelt I, McLean AS. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med. 2009;37:1594–603. doi: 10.1097/CCM.0b013e31819fb507.
    1. Annane D, Sebille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862–71.
    1. Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:2023–30. doi: 10.1016/S0140-6736(11)60607-7.
    1. Cicarelli DD, Vieira JE, Benseñor FE. Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial. Sao Paulo Med J. 2007;125:237–41. doi: 10.1590/S1516-31802007000400009.
    1. de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347:1549–56. doi: 10.1056/NEJMoa021334.
    1. Azoulay E, Canet E, Raffoux E, Lengliné E, Lemiale V, Vincent F, et al. Dexamethasone in patients with acute lung injury from acute monocytic leukemia. Eur Respir J. 2012;39:648–53. doi: 10.1183/09031936.00057711.
    1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R, the Consensus Committee. The American-European Consensus Conference on ARDS. Am J Respir Crit Care Med. 1994;149(3 Part 1):818–24.
    1. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526–33.
    1. Villar J, Pérez-Méndez L, López J, Belda J, Blanco J, Saralegui I, Suárez-Sipmann F, López J, Lubillo S, Kacmarek RM, HELP Network. An early PEEP/FIO2 trial identifies different degrees of lung injury in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2007;176:795–804.
    1. The Acute Respiratory Distress Syndrome Network Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301–8. doi: 10.1056/NEJM200005043421801.
    1. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29. doi: 10.1097/00003246-198510000-00009.
    1. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138:720–3. doi: 10.1164/ajrccm/138.3.720.
    1. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793–800.
    1. Villar J, Manzano JJ, Blazquez MA, Lubillo S, Villalobos J, Quintana J. Multiple system organ failure in acute respiratory failure. J Crit Care. 1991;6:75–80. doi: 10.1016/0883-9441(91)90011-H.
    1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250–6.
    1. Bell RC, Coalson JJ, Smith JD, Johanson WG., Jr Multiple organ system failure and infection in adult respiratory distress syndrome. Ann Intern Med. 1983;99:293–8. doi: 10.7326/0003-4819-99-3-293.
    1. Schoenfeld DA, Bernard GR, ARDS Network Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002;30:1772–7. doi: 10.1097/00003246-200208000-00016.
    1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;2:319–23. doi: 10.1016/S0140-6736(67)90168-7.
    1. Horita N, Hashimoto S, Miyazawa N, Fujita H, Kojima R, Inoue M, Ueda A, Ishigatsubo Y, Kaneko T. Impact of corticosteroids on mortality in patients with acute respiratory distress syndrome: a systematic review and meta-analysis. Intern Med. 2015;54:1473–9.
    1. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, Winzeler B, Bingisser R, Elsaesser H, Drozdov D, Arici B, Urwyler SA, Refardt J, Tarr P, Wirz S, Thomann R, Baumgartner C, Duplain H, Burki D, Zimmerli W, Rodondi N, Mueller B, Christ-Crain M. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385:1511–8.
    1. Maerz LL, Akhtar S. Perioperative glycemic management in 2011: paradigm shifts. Curr Opin Crit Care. 2011;17:370–5.
    1. Shorr AF, Chan CM. Clinical trials in the critically ill: practical and ethical challenges: comment on “Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support”. Arch Intern Med. 2011;171:1946–7. doi: 10.1001/archinternmed.2011.531.
    1. Burnham EL, Janssen WJ, Riches DW, Moss M, Downey GP. The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J. 2014;43:276–85. doi: 10.1183/09031936.00196412.
    1. Meduri GU, Bridges L, Shih MC, Marik PE, Siemieniuk RA, Kocak M. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med. 2016;42(5):829–40. doi: 10.1007/s00134-015-4095-4.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться